ProQR Therapeutics N.V EBITDA Growth & History (PRQR)

ProQR Therapeutics N.V's calculated EBITDA was −€54.9M for fiscal 2021.

View full ProQR Therapeutics N.V company overview

ProQR Therapeutics N.V annual ebitda history

ProQR Therapeutics N.V annual ebitda

Fiscal yearPeriod endedEBITDAChangeGrowth
20212021-12-31−€54.9M−€14.9M
20202020-12-31−€40.0M€15.4M
20192019-12-31−€55.4M−€20.1M
20182018-12-31−€35.3M€4.1M
20172017-12-31−€39.4M−€1.1M
20162016-12-31−€38.3M−€11.8M
20152015-12-31−€26.5M

ProQR Therapeutics N.V ebitda trends

Over the last five reported fiscal years, ProQR Therapeutics N.V's ebitda decreased from −€38.3M to −€54.9M, a change of −€16.6M. The latest reported quarter, Q3 2023, shows −€6.7M.

About the metric

What EBITDA means

EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.

Calculation and source

How TickerStat calculates EBITDA

TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review ProQR Therapeutics N.V filings at SEC.gov ↗